TNGX NASDAQ
Tango Therapeutics, Inc.
1W: -13.6%
1M: -23.1%
3M: +63.6%
YTD: +127.3%
1Y: +1253.3%
3Y: +465.5%
5Y: +87.8%
$20.30
-0.33 (-1.60%)
Pre-Market: $21.39 (+1.09, +5.39%)
Weekly Expected Move ±13.8%
$15
$18
$21
$23
$26
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.4B
52W Range1.72-28.41
Volume1,879,966
Avg Volume3,441,313
Beta1.22
Dividend—
Analyst Ratings
Company Info
CEOMalte Peters
Employees155
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-03
Websitetangotx.com
100 Binney Street
Boston, MA 02142
US
Boston, MA 02142
US
857 320 4900
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Latest News
Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX) - Seeking Alpha
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed? - Yahoo Finance
Assessing Tango Therapeutics (TNGX) Valuation After Trial Progress And Leadership Changes - simplywall.st
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Crystal Adam | M-Exempt | 27,000 | $5.20 | 2026-05-01 |
| Crystal Adam | M-Exempt | 27,000 | $5.20 | 2026-05-01 |
| Crystal Adam | S-Sale | 25,900 | $21.19 | 2026-05-01 |
| Crystal Adam | S-Sale | 1,100 | $22.00 | 2026-05-01 |
| Gall Matthew | A-Award | 240,000 | $20.98 | 2026-05-01 |